SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jones T.The role of positron emission tomography within the spectrum of medical imaging. Eur J Nucl Med1996;23:20711.
  • 2
    Tomasi G, Turkheimer F, Aboagye E.Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. Mol Imaging Biol2012;14:13146.
  • 3
    Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM.Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med1975;16:21024.
  • 4
    Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al.A combined PET/CT scanner for clinical oncology. J Nucl Med2000;41:136979.
  • 5
    Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME.A tabulated summary of the FDG PET literature. J Nucl Med2001;42 Suppl:1S93S.
  • 6
    Tan AL, Keen HI, Emery P, McGonagle D.Imaging inflamed synovial joints. Methods Mol Med2007;135:326.
  • 7
    Larson SM.Cancer or inflammation? A holy grail for nuclear medicine. J Nucl Med1994;35:16535.
  • 8
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988;31:31524.
  • 9
    Zasadny KR, Wahl RL.Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology1993;189:84750.
  • 10
    Palmer WE, Rosenthal DI, Schoenberg OI, Fischman AJ, Simon LS, Rubin RH, et al.Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology1995;196:64755.
  • 11
    Beckers C, Ribbens C, Andre B, Marcelis S, Kaye O, Mathy L, et al.Assessment of disease activity in rheumatoid arthritis with 18F-FDG PET. J Nucl Med2004;45:95664.
  • 12
    Kubota K, Ito K, Morooka M, Mitsumoto T, Kurihara K, Yamashita H, et al.Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med2009;23:78391.
  • 13
    Tateishi U, Imagawa T, Kanezawa N, Okabe T, Shizukuishi K, Inoue T, et al.PET assessment of disease activity in children with juvenile idiopathic arthritis. Pediatr Radiol2010;40:17818.
  • 14
    Okamura K, Yonemoto Y, Arisaka Y, Takeuchi K, Kobayashi T, Oriuchi N, et al.The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology (Oxford)2012;51:148491.
  • 15
    Vijayant V, Sarma M, Aurangabadkar H, Bichile L, Basu S.Potential of 18F-FDG-PET as a valuable adjunct to clinical and response assessment in rheumatoid arthritis and seronegative spondyloarthropathies. World J Radiol2012;4:4628.
  • 16
    Goerres GW, Forster A, Uebelhart D, Seifert B, Treyer V, Michel B, et al.F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med2006;31:38690.
  • 17
    Roivainen A, Hautaniemi S, Mottonen T, Nuutila P, Oikonen V, Parkkola R, et al.Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging2013;40:40310.
  • 18
    Beckers C, Jeukens X, Ribbens C, Andre B, Marcelis S, Leclercq P, et al.18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging2006;33:27580.
  • 19
    Elzinga EH, van der Laken CJ, Comans EF, Lammertsma AA, Dijkmans BA, Voskuyl AE.2-deoxy-2-[F-18]fluoro-d-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol2007;9:35760.
  • 20
    Taniguchi Y, Arii K, Kumon Y, Fukumoto M, Ohnishi T, Horino T, et al.Positron emission tomography/computed tomography: a clinical tool for evaluation of enthesitis in patients with spondyloarthritides. Rheumatology (Oxford)2010;49:34854.
  • 21
    Okabe T, Shibata H, Shizukuishi K, Yoneyama T, Inoue T, Tateishi U.F-18 FDG uptake patterns and disease activity of collagen vascular diseases-associated arthritis. Clin Nucl Med2011;36:3504.
  • 22
    Danfors T, Bergstrom M, Feltelius N, Ahlstrom H, Westerberg G, Langstrom B.Positron emission tomography with 11C-d-deprenyl in patients with rheumatoid arthritis: evaluation of knee joint inflammation before and after intra-articular glucocorticoid treatment. Scand J Rheumatol1997;26:438.
  • 23
    Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Mottonen T, et al.Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-d-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum2003;48:307784.
  • 24
    Van der Laken CJ, Elzinga EH, Kropholler MA, Molthoff CF, van der Heijden JW, Maruyama K, et al.Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum2008;58:33505.
  • 25
    Polisson RP, Schoenberg OI, Fischman A, Rubin R, Simon LS, Rosenthal D, et al.Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum1995;38:81925.
  • 26
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL.Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum1995;38:448.
  • 27
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al.A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford)2003;42:24457.
  • 28
    Chaudhari AJ, Bowen SL, Burkett GW, Packard NJ, Godinez F, Joshi AA, et al.High-resolution 18F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur J Nucl Med Mol Imaging2010;37:1047.
  • 29
    Kalicke T, Schmitz A, Risse JH, Arens S, Keller E, Hansis M, et al.Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases. Eur J Nucl Med2000;27:5248.
  • 30
    Linnman C, Appel L, Fredrikson M, Gordh T, Soderlund A, Langstrom B, et al.Elevated [11C]-D-deprenyl uptake in chronic whiplash associated disorder suggests persistent musculoskeletal inflammation. PLoS One2011;6:e19182.
  • 31
    Wunder A, Straub RH, Gay S, Funk J, Muller-Ladner U.Molecular imaging: novel tools in visualizing rheumatoid arthritis. Rheumatology (Oxford)2005;44:13419.
  • 32
    Lamare F, Hinz R, Gaemperli O, Pugliese F, Mason JC, Spinks T, et al.Detection and quantification of large-vessel inflammation with 11C-(R)-PK11195 PET/CT. J Nucl Med2011;52:339.
  • 33
    Baillet A, Gaujoux-Viala C, Mouterde G, Pham T, Tebib J, Saraux A, et al.Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford)2011;50:113747.
  • 34
    Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Ostergaard M.Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum2003;48:95562.
  • 35
    Ostergaard M, Lorenzen I, Henriksen O.Dynamic gadolinium-enhanced MR imaging in active and inactive immunoinflammatory gonarthritis. Acta Radiol1994;35:27581.
  • 36
    Gent YY, Voskuyl AE, Kloet RW, van Schaardenburg D, Hoekstra OS, Dijkmans BA, et al.Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis Rheum2012;64:626.
  • 37
    Sato M, Inubushi M, Shiga T, Hirata K, Okamoto S, Kamibayashi T, et al.Therapeutic effects of acupuncture in patients with rheumatoid arthritis: a prospective study using 18F-FDG-PET. Ann Nucl Med2009;23:3116.
  • 38
    Elzinga EH, van der Laken CJ, Comans EF, Boellaard R, Hoekstra OS, Dijkmans BA, et al.18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med2011;52:7780.
  • 39
    Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Diseases Group.Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum1990;33:47784.
  • 40
    Duet M, Pouchot J, Liote F, Faraggi M.Role for positron emission tomography in skeletal diseases. Joint Bone Spine2007;74:1423.
  • 41
    Dumarey N, Egrise D, Blocklet D, Stallenberg B, Remmelink M, del Marnol V, et al.Imaging infection with 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med2006;47:62532.
  • 42
    Kumar R, Basu S, Torigian D, Anand V, Zhuang H, Alavi A.Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev2008;21:20924.
  • 43
    Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL.Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med1998;25:123843.
  • 44
    Zhuang H, Yu JQ, Alavi A.Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am2005;43:12134.
  • 45
    Dorward DA, Lucas CD, Rossi AG, Haslett C, Dhaliwal K.Imaging inflammation: molecular strategies to visualize key components of the inflammatory cascade, from initiation to resolution. Pharmacol Ther2012;135:18299.
  • 46
    Gu JT, Nguyen L, Chaudhari AJ, Mackenzie JD.Molecular characterization of rheumatoid arthritis with magnetic resonance imaging. Top Magn Reson Imaging2011;22:619.
  • 47
    Rosenstein M.Diagnostic reference levels for medical exposure of patients: ICRP guidance and related ICRU quantities. Health Phys2008;95:52834.
  • 48
    Picano E.Sustainability of medical imaging. BMJ2004;328:57880.
  • 49
  • 50
    Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al.FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging. Version 1.0. Eur J Nucl Med Mol Imaging2010;37:181200.
  • 51
    Wahl RL, Jacene H, Kasamon Y, Lodge MA.From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med2009;50 Suppl 1:122S50S.
  • 52
    Miese F, Scherer A, Ostendorf B, Heinzel A, Lanzman RS, Kropil P, et al.Hybrid 18F-FDG PET-MRI of the hand in rheumatoid arthritis: initial results. Clin Rheumatol2011;30:124750.
  • 53
    Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009;6:e1000097.